ADVA
14.7.2020 09:02:09 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that it’s partnering with OTN Systems to address key connectivity challenges for industrial applications. The companies are teaming up to offer joint end-to-end networking solutions built with best-in-class technology and specifically designed for the industry sector. Now customers in transportation, oil and gas, mining and electrical power utilities can smoothly transition from their legacy SONET/SDH infrastructure and realize the benefits of packet transport. Featuring OTN Systems’ XTran MPLS-TP layer combined with ADVA FSP 3000 OLS technology, the tailor-made solutions are ruggedized for the harshest environments. They also provide stringent synchronization and comprehensive in-service monitoring, ensuring the levels of availability needed for the most advanced industrial demands.
”By joining forces with ADVA, we’re giving customers the full benefits of our combined innovation and expertise. Our companies share a goal of helping all industries on their digital transformation journeys. By delivering integrated end-to-end networks that precisely meet sector-specific requirements, we’re empowering our customers to take that next step,” said Jurgen Michielsen, CTO, OTN Systems. “From transportation to electric utilities, today’s industrial networks operators are looking for a seamless way to evolve their old SONET/SDH infrastructure to high-capacity packet-based network technology. The joint solution allows customers to make the jump to the next generation of telecom architecture simple, risk-free and extremely cost-effective.”
To keep pace with the demands of new applications, industrial networks must deliver greater bandwidth and improved quality of service. They need technology that supports an easy transition from increasingly obsolete SONET/SDH networks to packet-optical transport architectures. That’s precisely what ADVA and OTN Systems’ joint solutions provide. They enable operational infrastructure to cater for ever-increasing amounts of data traffic and support industrial automation. The combined solutions include the ADVA FSP 3000 OLS, which efficiently transports wavelengths over long distances using multiplexing, amplification, dispersion compensation, power leveling and wavelength routing. This is combined with OTN Systems’ XTran multi-service MPLS-TP platform designed for industrial applications. Growing security threats are also addressed with the protection of ADVA FSP 3000 ConnectGuard™ Optical encryption as well as strict synchronization needs with ADVA’s Oscilloquartz portfolio.
“We’re teaming up with OTN Systems to deliver industrial connectivity with a unique set of benefits. Together we can provide the most reliable and secure end-to-end networking solutions on the market – solutions that are fully optimized for next-generation industrial applications and specifically designed to withstand the most extreme environments,” commented Christoph Glingener, CTO, ADVA. “Our FSP 3000 enables industrial networks to minimize both cost per bit and operational efforts. Our joint customers can also further enhance performance and reduce operating costs with our ADVA ALM fiber monitoring solution. This gives industrial network operators full control with real-time insight into the fiber plant. What’s more, our Oscilloquartz technology range ensures the precise synchronization needed for ultra-low latency use cases.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About OTN Systems
OTN systems is a leading supplier of mission-critical telecommunication solutions to industrial customers for more than 30 years. The company has developed a unique next generation platform tailored for industrial applications. XTran is a flexible, state-of-the-art product allowing customers to go full packet. Its underlying MPLS-TP technology avoids the complexity of generic telecom solutions developed for service providers. XTran secures reliable operations in a harsh environments, while its management system (TXCare) supports an intuitive and simple handling. Since its market introduction back in 2014, more than 100 customers worldwide have deployed XTran. For more information on our product and services offering, please visit us at www.otnsystems.com
, allowing you to fully appreciate how “we make MPLS for Operational Telecom easy.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714005053/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom